155 related articles for article (PubMed ID: 31501052)
1. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis.
Barth P; Bruijnzeel P; Wach A; Sellier Kessler O; Hooftman L; Zimmermann J; Naue N; Huber B; Heimbeck I; Kappeler D; Timmer W; Chevalier E
J Cyst Fibros; 2020 Mar; 19(2):299-304. PubMed ID: 31501052
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics and neutrophil elastase inhibitory effects of Sivelestat: A randomized, double-blind, placebo-controlled single- and multiple-dose escalation study in Chinese healthy subjects.
Li K; Dong L; Gao S; Zhang J; Feng Y; Gu L; Yang J; Liu X; Wang Y; Mao Z; Jiang D; Xia Z; Zhang G; Tang J; Ma P; Zhang W
Eur J Pharm Sci; 2024 Apr; 195():106723. PubMed ID: 38336251
[TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
[TBL] [Abstract][Full Text] [Related]
6. Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis.
Kummarapurugu AB; Afosah DK; Sankaranarayanan NV; Navaz Gangji R; Zheng S; Kennedy T; Rubin BK; Voynow JA; Desai UR
J Biol Chem; 2018 Aug; 293(32):12480-12490. PubMed ID: 29903912
[TBL] [Abstract][Full Text] [Related]
7. Effects of cystic fibrosis airway secretions on rat lung: role of neutrophil elastase.
Rees DD; Brain JD
Am J Physiol; 1995 Aug; 269(2 Pt 1):L195-202. PubMed ID: 7653580
[TBL] [Abstract][Full Text] [Related]
8. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis.
Guyot N; Butler MW; McNally P; Weldon S; Greene CM; Levine RL; O'Neill SJ; Taggart CC; McElvaney NG
J Biol Chem; 2008 Nov; 283(47):32377-85. PubMed ID: 18799464
[TBL] [Abstract][Full Text] [Related]
9. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor.
Delacourt C; Hérigault S; Delclaux C; Poncin A; Levame M; Harf A; Saudubray F; Lafuma C
Am J Respir Cell Mol Biol; 2002 Mar; 26(3):290-7. PubMed ID: 11867337
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.
Taylor-Cousar JL; Wiley C; Felton LA; St Clair C; Jones M; Curran-Everett D; Poch K; Nichols DP; Solomon GM; Saavedra MT; Accurso FJ; Nick JA
J Cyst Fibros; 2015 Mar; 14(2):228-36. PubMed ID: 25466700
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of neutrophil elastase in CF sputum by L-658,758.
Rees DD; Brain JD; Wohl ME; Humes JL; Mumford RA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1201-6. PubMed ID: 9399994
[TBL] [Abstract][Full Text] [Related]
12. Cytokine concentrations and neutrophil elastase activity in bronchoalveolar lavage and induced sputum from patients with cystic fibrosis, mild asthma and healthy volunteers.
McGarvey LP; Dunbar K; Martin SL; Brown V; Macmahon J; Ennis M; Elborn JS
J Cyst Fibros; 2002 Dec; 1(4):269-75. PubMed ID: 15463826
[TBL] [Abstract][Full Text] [Related]
13. Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis.
Ordoñez CL; Kartashov AI; Wohl ME
J Pediatr; 2004 Nov; 145(5):689-92. PubMed ID: 15520781
[TBL] [Abstract][Full Text] [Related]
14. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
Zeitlin PL; Diener-West M; Callahan KA; Lee S; Talbot CC; Pollard B; Boyle MP; Lechtzin N
Ann Am Thorac Soc; 2017 Feb; 14(2):220-229. PubMed ID: 28006108
[TBL] [Abstract][Full Text] [Related]
15. AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis.
Kristensson C; Åstrand A; Donaldson S; Goldwater R; Abdulai R; Patel N; Gardiner P; Tehler U; Mercier AK; Olsson M; Ersdal E; Mäenpää J; Bramer T; Malmgren A; Bennett W; Keen C
J Cyst Fibros; 2022 Jul; 21(4):684-690. PubMed ID: 35227647
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques.
Oriano M; Terranova L; Sotgiu G; Saderi L; Bellofiore A; Retucci M; Marotta C; Gramegna A; Miglietta D; Carnini C; Marchisio P; Chalmers JD; Aliberti S; Blasi F
Pulm Pharmacol Ther; 2019 Dec; 59():101856. PubMed ID: 31626976
[TBL] [Abstract][Full Text] [Related]
17. Alpha 1-proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum.
Hansen G; Schuster A; Zubrod C; Wahn V
Respiration; 1995; 62(3):117-24. PubMed ID: 7569330
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.
Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M
J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705
[TBL] [Abstract][Full Text] [Related]
19. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis.
Gibson RL; Retsch-Bogart GZ; Oermann C; Milla C; Pilewski J; Daines C; Ahrens R; Leon K; Cohen M; McNamara S; Callahan TL; Markus R; Burns JL
Pediatr Pulmonol; 2006 Jul; 41(7):656-65. PubMed ID: 16703579
[TBL] [Abstract][Full Text] [Related]
20. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis.
App EM; Baran D; Dab I; Malfroot A; Coffiner M; Vanderbist F; King M
Eur Respir J; 2002 Feb; 19(2):294-302. PubMed ID: 11866009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
